Evidence map›Paper›PMID 26129894›Full record

ArticleNature communications2015

A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis.

Sabu Abraham, Margherita Scarcia, Richard D Bagshaw, Kathryn McMahon, Gary Grant, Tracey Harvey, Maggie Yeo, Filomena O G Esteves, Helene H Thygesen, Pamela F Jones and 8 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 84 citations in OpenAlex.

  1. Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients.Proceedings of the National Academy of Sciences of the United States of America · 2015
    Trial
  2. Article
  3. Endothelial RhoGEF Trio is involved in angiogenesis.Vascular biology (Bristol, England) · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Fundamental research · 2023
    Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 4 institutions in 2 countries.

Sabu AbrahamInstitute of Cancer Research, Division of Cancer Biology, 237 Fulham Road, London SW3 6JB, UK.
Margherita ScarciaLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Richard D BagshawSamuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, M5G 1X5 Ontario, Canada.
Kathryn McMahonLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Gary GrantLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Tracey HarveyLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Maggie YeoInstitute of Cancer Research, Division of Cancer Biology, 237 Fulham Road, London SW3 6JB, UK.
Filomena O G EstevesLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Helene H ThygesenLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Pamela F JonesLeeds Institutes of Molecular Medicine, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Valerie SpeirsLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Andrew M HanbyLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Peter J SelbyLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Mihaela LorgerLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
T Neil DearLeeds Institutes of Molecular Medicine, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
Tony PawsonSamuel Lunenfeld Research Institute, Mount Sinai Hospital, 600 University Avenue, Toronto, M5G 1X5 Ontario, Canada.
Christopher J MarshallInstitute of Cancer Research, Division of Cancer Biology, 237 Fulham Road, London SW3 6JB, UK.
Georgia MavriaLeeds Institute of Cancer and Pathology, University of Leeds, St James' University Hospital, Beckett Street, Leeds LS9 7TF, UK.
University of Leeds · GBSt James's University Hospital · GBInstitute of Cancer Research · GBLunenfeld-Tanenbaum Research Institute · CA

Funding

Cancer Research UK 16512Cancer Research UK C107/A7631CIHR MOP-6849Department of Health RP-PG-0707-10101
6 · The paper itself

Abstract

During angiogenesis, Rho-GTPases influence endothelial cell migration and cell-cell adhesion; however it is not known whether they control formation of vessel lumens, which are essential for blood flow. Here, using an organotypic system that recapitulates distinct stages of VEGF-dependent angiogenesis, we show that lumen formation requires early cytoskeletal remodelling and lateral cell-cell contacts, mediated through the RAC1 guanine nucleotide exchange factor (GEF) DOCK4 (dedicator of cytokinesis 4). DOCK4 signalling is necessary for lateral filopodial protrusions and tubule remodelling prior to lumen formation, whereas proximal, tip filopodia persist in the absence of DOCK4. VEGF-dependent Rac activation via DOCK4 is necessary for CDC42 activation to signal filopodia formation and depends on the activation of RHOG through the RHOG GEF, SGEF. VEGF promotes interaction of DOCK4 with the CDC42 GEF DOCK9. These studies identify a novel Rho-family GTPase activation cascade for the formation of endothelial cell filopodial protrusions necessary for tubule remodelling, thereby influencing subsequent stages of lumen morphogenesis.

Indexed as

Neovascularization, PathologicNeovascularization, PhysiologicAnimalscdc42 GTP-Binding ProteinCytoskeletonGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsHumansHuman Umbilical Vein Endothelial CellsMice, Inbred C57BLMice, KnockoutPseudopodiarho GTP-Binding ProteinsVascular Endothelial Growth Factor Acdc42 GTP-Binding ProteinDOCK4 protein, humanDOCK9 protein, humanGTPase-Activating ProteinsGuanine Nucleotide Exchange FactorsRHOG protein, humanrho GTP-Binding ProteinsVascular Endothelial Growth Factor A

Identifiers

PMID26129894
PMCPMC4507007
OpenAlexW1885268003

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.